Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Hupperts

Showing results (71-80 of 115) with videos related to

Pageof 12
Sort By:
Journal of the Neurological Sciences|August 15, 2018
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapyIlya Kister, Tim Spelman, Francesco Patti, et al.
BMC Neurology|April 1, 2011
Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study)Peter J Jongen, Gerald Hengstman, Raymond Hupperts, et al.
Annals of Clinical and Translational Neurology|April 25, 2015
Comparative efficacy of switching to natalizumab in active multiple sclerosisTimothy Spelman, Tomas Kalincik, Annie Zhang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2014
Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosisLaura de Bock, Klaartje Somers, Judith Fraussen, et al.
Trials|January 28, 2014
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trialMelissa Cambron, Jop Mostert, Patrick Haentjens, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2018
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosisMyintzu Min, Tim Spelman, Alessandra Lugaresi, et al.
JAMA Neurology|July 28, 2020
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple SclerosisNathaniel Lizak, Charles B Malpas, Sifat Sharmin, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2020
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS scoreAmy Kunchok, Jeannette Lechner-Scott, Franco Granella, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Pageof 12

Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
Journal of the Neurological Sciences|August 15, 2018
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapyIlya Kister, Tim Spelman, Francesco Patti, et al.
BMC Neurology|April 1, 2011
Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study)Peter J Jongen, Gerald Hengstman, Raymond Hupperts, et al.
Annals of Clinical and Translational Neurology|April 25, 2015
Comparative efficacy of switching to natalizumab in active multiple sclerosisTimothy Spelman, Tomas Kalincik, Annie Zhang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2014
Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosisLaura de Bock, Klaartje Somers, Judith Fraussen, et al.
Trials|January 28, 2014
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trialMelissa Cambron, Jop Mostert, Patrick Haentjens, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2018
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosisMyintzu Min, Tim Spelman, Alessandra Lugaresi, et al.
JAMA Neurology|July 28, 2020
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple SclerosisNathaniel Lizak, Charles B Malpas, Sifat Sharmin, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2020
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS scoreAmy Kunchok, Jeannette Lechner-Scott, Franco Granella, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Pageof 12